The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyDrug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and ChallengesReversal of oral anticoagulationThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryAnticoagulant therapy in pediatricsClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanReversal of target-specific oral anticoagulantsProtocol in managing oral surgical patients taking dabigatranComparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber modelThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literatureAtrial fibrillation management in older heart failure patients: a complex clinical problemNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsAnticoagulants and the propagation phase of thrombin generationPharmacometric characterization of dabigatran hemodialysisUse of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data.Direct thrombin inhibitors.Hemorrhagic complications associated with dabigatran use.Trends in the development of oral anticoagulants.The role of prothrombin complex concentrates in reversal of target specific anticoagulants.Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyIncidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Reversal of novel oral anticoagulants in patients with major bleeding.Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide studyA proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeCoagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatranPharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.Update on anti-coagulation in atrial fibrillation.Enhanced elimination of dabigatran through extracorporeal methods.Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.Selecting antithrombotic therapy for patients with atrial fibrillation.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
P2860
Q24185813-D8D76359-97F2-4EBC-96CE-0CD70F782BB1Q26766303-729234A2-4B51-4508-92DF-CCA98B0C3E30Q26798105-7D926450-E942-4099-8BBA-6011DDA9DDFCQ26827835-EEDBF263-C869-453F-9F84-02BD306A8970Q26828439-8D88CDC4-4554-4705-A4CC-CEEE1F93C8C0Q26829750-2D7EC3BF-E213-4B7C-A60B-A70BCB714C1BQ26864411-D7B857A7-2218-461C-8D8A-A4B323E457C2Q27003866-BE8CF00D-2F66-4EBF-BCB0-BE6ADCABC513Q27006890-474A368E-D195-43B3-A819-3C7FE143CC5DQ27330363-4E4C99EE-4ADB-4A43-9692-90FB0A07E03CQ27497485-712AC473-2A6D-45D7-91BF-5B69A07CD995Q28076170-FBDEC0DE-405B-4442-94A4-066022CF06A0Q28080616-7A3AEC79-43D2-40D5-8E22-DA1F0C736A26Q28742536-CAB0E948-E502-41E2-BE3C-C95449BBC48EQ29584461-ADBED479-70DB-4920-AEBA-CB179790D684Q31066944-E903E685-78DF-4B11-81EB-B12927D64AA1Q33393692-7B1E47D8-D1B0-4ED7-A3EC-C5FF35A05314Q33403265-F2EFC704-187B-4AFF-BB4C-640ABAC01083Q33424198-B18D0A89-6031-400A-BF27-5A65CE524640Q33582537-2A572577-CD28-4866-82EC-3A40E802B6A0Q33804810-13AA3822-FCAF-403C-BA2D-7F4591C4D12BQ33891915-67CF5772-BD3F-4089-975C-8A5094022361Q34035190-998847FF-E312-45C1-8EB4-EBED90CE823DQ34223524-15E1FEFE-E69B-4FA9-9DD3-ABB6245DA878Q34252907-482131E4-7BE3-4571-A4B2-961DE9AA27CFQ34326655-6C318DE1-4204-43DD-8A8D-CA4BF49855F2Q34343069-24C820C8-9DA5-41F9-942D-5E6D1FD44B39Q34571082-F05BAF0F-933C-40BB-B982-00B74571157AQ34571099-37DAB6C3-D10B-4B24-8A33-69130851E16AQ34611004-2434A13C-8754-47BF-9B2C-DAB1E4AAF210Q34651036-D7C4622F-5D1F-4784-A9AF-E1619B01BA04Q34651051-707C086B-FD1F-41F2-934D-A9F9A969FAC9Q34671648-F0645D7D-657D-4661-B1C9-B17EB3F7D0C3Q35172841-92B20095-E42B-4DCC-8FC4-12E4118C3638Q35210137-0D697899-68CE-4A5F-91C0-BB4D820E5B3FQ35536242-3A180458-BCC4-4666-9C7E-A51A611C3E55Q35650380-55500DA1-A751-4DC2-ACE8-16B77DED6F7CQ35683869-90C81829-F06B-4441-8CDA-ACB8093DCCCAQ35768553-625BDE84-E2CF-4D68-8CEA-25803A57F6D1Q35877331-A1C2C99C-9B0B-432B-9B1E-1572533DAB75
P2860
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@en
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@nl
type
label
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@en
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@nl
prefLabel
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@en
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@nl
P2093
P356
P1476
The metabolism and disposition ...... ibitor, dabigatran, in humans.
@en
P2093
Eva Ludwig-Schwellinger
Joachim Stangier
Stefan Blech
Thomas Ebner
Willy Roth
P304
P356
10.1124/DMD.107.019083
P577
2007-11-15T00:00:00Z